explore -WSS

explore

author：focus 2025-10-02 19:38:17 - browse：89184

A pharmacist hands a box of Wegovy — first opinion coverage from STAT — Bloomberg photo by George Frey

LONDON — Novo Nordisk said Wednesday that it had started to increase the availability of its blockbuster obesity drug Wegovy for new patients in the United States, after massive demand and a supply crunch had led it to limit doses last May.

The announcement that Novo was making more of its lower-dose starter product available as of this month came as the company reported its 2023 earnings, with sales up by 36% and operating profit up 44% at constant exchange rates, driven by enormous sales of Wegovy and Ozempic, the company’s sister drug for diabetes. The company also projected double-digit growth in sales and operating profit for 2024.

“I am pleased to state that we are now enabling more new U.S. patients to initiate treatment by more than doubling the amount of lower-dose strength Wegovy compared to previous months,” Novo CEO Lars Fruergaard Jørgensen said on a call with reporters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Alnylam reports growth in sales of rare disease treatments

hotspot

WSS

CDC recommends RSV monoclonal antibody for infants

Finland to offer bird flu vaccine to select groups of people, a possible global first

CDC recommends RSV monoclonal antibody for infants

Congress needs to close a vaccine

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

ASCO Daily Recap: CAR

leisure time

explore

entertainment

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

In age of alternative facts, a scholarly course on calling out crap

Illumina board agrees to spin off Grail, as divestment plans proceed

Drug repurposing or repositioning? The language matters

CDC recommends RSV monoclonal antibody for infants

United colonoscopy coverage change 'may cost lives,' doctors say

Elevance PBM president out as customers face prescription chaos

Wildfire smoke exposes gaps in outdoor worker protections

Late stage cancers on the rise after pandemic delayed screenings

focus

It costs an awful lot of money to give away a kidney

FDA approves Moderna’s RSV vaccine, its second licensed product

ASCO Daily Recap: CAR

Sutter Health’s antitrust win overturned by appeals court

Stopping antidepressants leads to symptoms for 1 in 6 patients

For pregnant people, addiction treatment shouldn't mean a call to child protective services

focus

hotspot

focus

leisure time